PhoenixBio Co., Ltd. (6190) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for PhoenixBio Co., Ltd. (6190:JPX), powered by AI.

Current Price
¥484
P/E Ratio
-4.4
Market Cap
2.0B
Sector
Healthcare
What is the PhoenixBio Co., Ltd. stock price forecast?

PhoenixBio Co., Ltd. is currently trading at ¥484. View real-time AI analysis on Alpha Lenz.

What is PhoenixBio Co., Ltd. insider trading activity?

View the latest insider trading data for PhoenixBio Co., Ltd. on Alpha Lenz.

What is PhoenixBio Co., Ltd.'s P/E ratio?

PhoenixBio Co., Ltd.'s P/E ratio is -4.4.

PhoenixBio Co., Ltd.

¥484.00
JPX6190
Ask about PhoenixBio Co., Ltd.'s future dividend policy...
Alpha Chat Insight

PhoenixBio Co., Ltd. trades at a P/E of -4.4 (undervalued) with modest ROE of -28.4%.

Ask for details

Company Overview

PhoenixBio Co., Ltd. is a biotechnology company dedicated to the development of cutting-edge bio-research products. The primary focus of PhoenixBio is on creating and distributing high-quality human liver-based research tools and technology platforms. These products are essential for pharmaceutical companies and research institutions engaged in drug discovery and development, particularly in areas like toxicology and pharmacology where precise human liver models can significantly impact research outcomes. With a commitment to innovation, PhoenixBio primarily serves the scientific and medical research communities, facilitating advancements in understanding liver diseases and their treatments. Located in Japan, PhoenixBio has carved out a significant niche by offering proprietary bioengineered models that simulate human liver functions, thus enhancing the drug discovery process. Its role in the market is crucial, acting as a bridge between pure scientific research and practical applications in medicine, particularly in developing safer and more efficient pharmaceuticals.

CEOTakashi Shimada
SectorHealthcare
IndustryBiotechnology
Employees69

Company Statistics

(FY 2025)

Profile

Market Cap¥1.96B
Revenue¥1.54B
Shares Out0.00
Employees69

Margins

Gross72.51%
EBITDA-5.90%
Operating-9.22%
Pre-Tax-28.08%
Net-29.13%

Valuation

P/E-4.36
P/B1.43
EV/Sales1.27
EV/EBITDA-15.11
P/FCF-18.59

Growth (CAGR)

Rev 3Yr5.18%
Rev 5Yr3.29%
Op Inc 3YrN/A
Op Inc 5YrN/A
Net Inc 3YrN/A
Net Inc 5YrN/A

Returns

ROA-17.95%
ROE-28.39%
ROIC-17.10%

Financial Health

Cash & Cash Equivalents¥1.15B
Net Debt¥-229.45M
Debt/Equity67.37%
Interest CovN/A
Ask Alpha Chat

Frequently Asked Questions

Alpha Lenz
Singapore
CEO: Kyungtae Kim | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2025 Treasurer. All rights reserved.
PhoenixBio Co., Ltd. (Healthcare) Stock Forecast & Analysis ¥484 | Alpha Lenz